<DOC>
	<DOCNO>NCT01353040</DOCNO>
	<brief_summary>The purpose study characterize safety pharmacology single administration AVI-6003 , post-exposure prophylaxis candidate treatment Marburg virus .</brief_summary>
	<brief_title>Safety Study Single Administration Post-exposure Prophylaxis Treatment Marburg Virus</brief_title>
	<detailed_description>Marburg hemorrhagic fever rare human disease cause Marburg virus , filamentous , single-stranded , negative-sense RNA virus . In general , mortality rate associate Marburg virus outbreak range 23 % 88 % , high death rate see recent epidemic . No vaccine effective therapy available Marburg hemorrhagic fever . AVI-6003 experimental combination 2 phosphorodiamidate morpholino antisense oligomers positive charge select subunit ( PMOplusâ„¢ ) . These oligomers specifically target viral messenger RNA encode 2 Marburg virus protein think important viral replication host immune suppression . The present study design characterize safety , tolerability pharmacokinetics escalate single-administration dos AVI-6003 healthy human subject .</detailed_description>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Marburg Virus Disease</mesh_term>
	<criteria>Male female age 18 50 year good general health Volunteers must willing use barrier method contraception nonchildbearing potential Volunteers must willing undergo urine screen drug abuse Pregnancy breastfeed . Any clinically relevant abnormality physical examination , vital sign , ECG , clinical chemistry , hematology urinalysis Positive test human immunodeficiency virus , hepatitis B hepatitis C know history HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>